publication date: Sep. 22, 2016
Hepatocellular Carcinoma Study Confirms Association Between RFA Burn Time, OS In Patients Receiving ThermoDox
Celsion Corp. said NIH has conducted an independent retrospective analysis of data from the intent-to-treat population of the Company’s HEAT Study, a 701-patient study investigating ThermoDox, Celsion’s proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation in primary hepatocellular carcinoma.
The findings will be presented at an oral session Nov. 28, at the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America in Chicago.
Celsion is studying the use of RFA as a heat source both for tumor ablation and to activate ThermoDox as a means of treating the area surrounding the tumor, where untreated tumor may be present.
The NIH analysis, which sought to evaluate the correlation between RFA burn time per tumor volume (min/ml) and clinical outcome in patients treated with ThermoDox, concluded that increased burn time per tumor volume substantially improved survival in patients treated with RFA + ThermoDox compared to patients treated with RFA alone.
These findings are consistent with Celsion’s analysis of the HEAT Study data showing that in patients treated with RFA for more than 45 minutes, standardized RFA plus ThermoDox resulted in a statistically significant improvement in overall survival, compared to standardized RFA alone.
“Findings from the NIH’s independent analysis provide additional strong … Continue reading CCL 39-08 Study Confirms Association Between RFA Burn Time, OS In Patients Receiving ThermoDox
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us
and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.